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Abstract By proteolytic cleavage of insulin-like growth factor
binding proteins, the metalloproteinase pregnancy-associated
plasma protein-A (PAPP-A) is able to control the biological
activity of insulin-like growth factors. PAPP-A circulates in
pregnancy as a proteolytically inactive complex, disul¢de bound
to the proform of eosinophil major basic protein (proMBP). We
here demonstrate that co-transfection of mammalian cells with
PAPP-A and proMBP cDNA results in the formation of a
covalent PAPP-A/proMBP complex in which PAPP-A is inhib-
ited. Formation of the complex also occurs when PAPP-A and
proMBP synthesized separately are incubated. Complex forma-
tion was monitored by Western blotting, and by using an im-
munoassay speci¢c for the complex. Using mutagenesis, we fur-
ther demonstrate that the complex forms in a speci¢c manner
and depends on the presence of two proMBP cysteine residues.
Mutated proMBP, in which Cys-51 and -169 are replaced by
serine, is unable to form the covalent complex with PAPP-A.
Of particular interest, such mutated proMBP further lacks the
ability to inhibit PAPP-A. For the ¢rst time, this conclusively
demonstrates that proMBP is a proteinase inhibitor. We further
conclude that proMBP inhibits PAPP-A in an unusual manner,
not paralleled by other proteinase inhibitors of our knowledge,
which requires proMBP to be covalently bound to PAPP-A by
disul¢de bonds. ProMBP binding to PAPP-A most likely either
abrogates substrate access to the active site of PAPP-A or in-
duces a conformational change in the structure of PAPP-A, as
we, by further mutagenesis, were able to exclude that the inhib-
itory mechanism of proMBP is based on a cysteine switch-like
mechanism.
1 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
Key words: Proform of eosinophil major basic protein;
Pregnancy-associated plasma protein-A;
Insulin-like growth factor binding protein; Proteolysis ;
Proteinase inhibition
1. Introduction
Pregnancy-associated plasma protein-A (PAPP-A) is a 400
kDa dimeric protein, which belongs to the metzincin super-
family of metalloproteinases [1^3]. It regulates the availability
of insulin-like growth factor (IGF)-I and -II by cleavage of
IGF binding protein (IGFBP)-4 at one site, resulting in low-
ered a⁄nity for IGF [4,5]. IGFBP-5 [6] and -2 [7] are also
PAPP-A substrates in vitro, but their biological signi¢cance is
currently less clear.
PAPP-A functions in many biological systems, including
the ovary [8,9], the cardiovascular system [10,11], and the
skeletal system [12,13]. During human pregnancy, PAPP-A
is synthesized in the placenta [14] from which it is secreted
abundantly into the maternal circulation. PAPP-A exists there
primarily as a covalent, disul¢de-bound 2:2 complex of 500
kDa with the proform of eosinophil major basic protein
(proMBP) [15], also synthesized in the placenta, but in a dif-
ferent type of cell [14]. The proMBP polypeptide of 206 res-
idues is highly glycosylated [16,17] and migrates in sodium
dodecyl sulfate^polyacrylamide gel electrophoresis (SDS^
PAGE) as a smear above 50 kDa [15].
The mature, 117 residue MBP is known from the eosinophil
leukocyte as a cytotoxic protein, but no evidence suggests that
proMBP synthesized outside the eosinophil is proteolytically
processed. In the bone marrow, MBP is generated during
maturation of the eosinophils [18]. With a calculated isoelec-
tric point of 10.8, mature MBP is highly basic, but as the
propiece is highly acidic (pI=4.0), proMBP has an isoelectric
point of 6.0. The propiece is believed to mask the cytotoxicity
of MBP in eosinophils prior to its deposition in cytoplasmic
granules [19]. The three-dimensional structure of neither
PAPP-A nor proMBP is known, but the structure of the
mature MBP isolated from eosinophils was recently solved
[20].
Interestingly, the PAPP-A/proMBP complex in the mater-
nal circulation lacks proteolytic activity [21]. However, the
activity of unfractionated pregnancy serum against IGFBP-4
is caused by the existence of about 1% uncomplexed PAPP-A,
and possibly by a minor fraction of PAPP-A, that binds
proMBP in a 2:1 stoichiometry, suggesting that proMBP in-
hibits the activity of PAPP-A [21]. Furthermore, the activity
of endogenous PAPP-A of human ¢broblasts can be inhibited
by transfection with proMBP cDNA [22]. There are no re-
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ports of other proteins with inhibitory function towards
PAPP-A.
Herein, we describe a system that we have established to
generate the recombinant PAPP-A/proMBP complex in vitro.
We further describe the e¡ects of speci¢c mutations in
proMBP on complex formation and on inhibitory activity.
In particular, we unequivocally demonstrate that proMBP is
a proteinase inhibitor of PAPP-A, and that only covalently
bound proMBP is inhibitory.
2. Materials and methods
2.1. Plasmid constructs
Human placental oligo-dT-primed cDNA [23] was used as a tem-
plate to amplify cDNA encoding proMBP ([24], accession number
Y00809). Speci¢c primers containing an NheI site (5P-CGGCTAGC-
TAGCATGAAACTCCCCCTACTTCTG-3P) and an XhoI site (5P-
CGCCGCTCGAGTCAGTAGGAACAGATGAAAGG-3P) were used,
and the resulting polymerase chain reaction (PCR) product was blunt
end-ligated into pCR-Blunt II-TOPO (Invitrogen). The cDNA was
excised from this vector with NheI and XhoI and cloned into the
mammalian expression vector pcDNA3.1+ (Invitrogen) to generate
pcDNA3.1-proMBP. Mutagenesis of pcDNA3.1-proMBP was carried
out by overlap extension PCR [25]. In brief, outer primers were 5P-
CCCCATTGACGCAAATGGGCGG-3P (5P end) and 5P-AGGAA-
AGGACAGTGGGAGTGG-3P (3P end) (nt 760^781 and nt 1117^
1097, respectively, of pcDNA3.1+). Internal primers with an overlap
of V22 bp were used to generate mutated fragments that were di-
gested with NheI/XhoI and swapped into the wild-type construct.
Four mutants (proMBP-C89S, proMBP-C128S, proMBP-C147S,
proMBP-C201S) with single cysteine residues substituted by serine
were made. A double mutant (proMBP-C51S/C169S) was made by
two consecutive rounds of PCR, in which a C51S mutant of proMBP
was used as a template in the second round. All PCR reactions were
carried out with Pfu DNA polymerase (Promega), and all constructs
were veri¢ed by sequence analysis. Plasmid DNA for transfection was
prepared using the QIAprep Spin Kit (Qiagen).
2.2. Tissue culture and transfection
Human embryonic kidney 293T cells (293tsA1609neo) [26] were
maintained in high glucose Dulbecco’s modi¢ed Eagle’s medium sup-
plemented with 10% fetal bovine serum, 2 mM glutamine, non-essen-
tial amino acids, and gentamicin (Life Technologies). Cells were
plated onto 6 cm tissue culture dishes, and were transfected 18 h later
by calcium phosphate co-precipitation [27] using 10 Wg of plasmid
DNA. The cells were transfected with either a proMBP expression
vector or the PAPP-A expression vector [21], or co-transfected with
both. After a further 48 h the supernatants were harvested and cleared
by centrifugation.
2.3. Visualization of PAPP-A/proMBP complex formation
Formation of the PAPP-A/proMBP complex in culture medium of
co-transfected cells was visualized by Western blotting following sep-
aration by SDS^PAGE in 3^8% precast Tris-acetate gels (Invitrogen).
Prior to loading of the gel, samples were incubated in loading bu¡er
without heating. After electrophoresis, the protein was blotted onto a
polyvinylidene di£uoride membrane, and the blots were blocked 30
min with 2% skimmed-milk powder dissolved in 50 mM Tris, 500 mM
sodium chloride, 0.1% Tween 20, pH 9.0 (TST), and then washed and
equilibrated in TST. Primary antibody (mAb 234-2 for PAPP-A, and
mAb 234-10 for proMBP) [28] was diluted in TST containing 2%
skimmed-milk powder, and blots were incubated for 1 h at room
temperature. Incubation with peroxidase-conjugated secondary anti-
bodies (P0260, Dako) diluted in TST was done for 0.5 h at room
temperature. Proteins were visualized using enhanced chemilumines-
cence (ECL, Amersham). Similar experiments were carried out using
wild-type PAPP-A and mutated proMBP, as described in the text.
2.4. Determination of protein concentration by enzyme-linked
immunosorbent assay (ELISA)
Measurements of concentrations of PAPP-A and proMBP in cul-
ture supernatants were carried out by sandwich ELISAs, in which
polyclonal rabbit anti-(PAPP-A/proMBP) [16] was used for capture,
and monoclonal antibodies against PAPP-A (234-2) [28] or proMBP
(234-10) [29] followed by peroxidase-conjugated anti-(mouse IgG)
(P0260, Dako) were used for detection. Blocking was done using
phosphate-bu¡ered saline (PBS) with 2% bovine serum albumin
(BSA). For dilution of antibodies, PBS containing 0.01% Tween-20
(PBST) and 1% BSA was used. PBST was used for washing. Speci¢c
measurement of the PAPP-A/proMBP complex was carried out in a
double monoclonal assay using a PAPP-A monoclonal (234-5) for
capture and a biotinylated proMBP monoclonal (VRPM-2, V. Ro-
dacker, M. Overgaaard, K. Mortensen, H. Sperling-Petersen and C.
Oxvig, unpublished) and peroxidase-conjugated avidin (P0347, Dako)
for detection. In the latter assay, sample dilution and washing after
sample incubation were carried out using PBST to which 800 mM
sodium chloride was added. All standard curves were based on the 2:2
PAPP-A/proMBP complex puri¢ed from pregnancy serum [16].
2.5. In vitro formation of the PAPP-A/proMBP complex after separate
synthesis
Culture supernatants containing recombinant PAPP-A and
proMBP were mixed and incubated at 37‡C while shaking (800
rpm). The ¢nal concentration of PAPP-A subunit was 20 nM (4.0
Wg/ml), and the ¢nal concentration of proMBP subunit (wild-type
or mutant) was 200 nM (7.6 Wg/ml), but lower (20^40 nM) in experi-
ments in which the e¡ect of proMBP concentration was analyzed.
Samples were taken out and frozen at de¢ned time points from 0 to
72 h, and PAPP-A/proMBP complex formation was visualized by
Western blotting (see Section 2.3) and quanti¢ed by the complex
speci¢c ELISA (see Section 2.4). Mutants proMBP-C89S and
proMBP-C128S were ¢rst puri¢ed by a⁄nity chromatography using
mAbs 234-8 and -10 [28] coupled to cyanogen bromide-activated Se-
pharose 4B (Amersham Pharmacia Biotech), and then mixed with
medium from mock-transfected cells, as they were found to express
at a lower level than wild-type proMBP.
2.6. Measurements of proteolytic activity
Proteolytic activities of PAPP-A-containing samples were assayed
as described previously for IGFBP-4 and -5 [6], and IGFBP-2 [7]. In
brief, PAPP-A (0.6 nM, 0.12 Wg/ml) was incubated at 37‡C with
puri¢ed, 125I-labeled IGFBP-4 or -2 (10 nM, 0.30 Wg/ml) contained
in 50 mM Tris, 100 mM sodium chloride, 1 mM calcium chloride, pH
7.5. Incubations were carried out in the presence of added IGF-II (50
nM, 0.35 Wg/ml) (Bachem). Similarly, assays for proteolytic activity
against IGFBP-5 were carried out incubating with PAPP-A (0.2 nM,
0.04 Wg/ml) in the absence of added IGF-II. Samples of the reaction
mixtures, taken out at time points from 0 to 30 min, were separated
by non-reducing SDS^PAGE (10^20% Tris-glycine Laemmli gels).
The degree of cleavage was assessed by measuring band intensities
with a PhosphorImager (Molecular Dynamics), and plotted as a func-
tion of time after subtraction of background, as previously reported
[6].
3. Results and discussion
3.1. In vitro formation of the PAPP-A/proMBP complex
We co-transfected 293T cells with cDNAs encoding human
PAPP-A and proMBP, and analyzed the culture supernatant
by Western blotting using a monoclonal antibody against
PAPP-A (Fig. 1A). PAPP-A from co-transfected cells mi-
grated with a higher molecular weight compared to the
PAPP-A dimer secreted from cells transfected with PAPP-A
cDNA only (Fig. 1A, lane 4 vs. lane 2), for the ¢rst time
demonstrating complex formation between PAPP-A and
proMBP in vitro. Compared to the native PAPP-A/proMBP
complex puri¢ed from pregnancy serum (Fig. 1A, lane 3), the
recombinant complex migrated slightly faster, in agreement
with the known di¡erence in glycosylation between recombi-
nant and native PAPP-A [21], and a possible similar di¡erence
between recombinant and native proMBP. We cannot exclude
that a minor fraction of PAPP-A exists in a 2:1 complex with
proMBP, but no PAPP-A was detected at the position of
uncomplexed PAPP-A dimer in the co-transfection experi-
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ment. The same samples were also analyzed with a monoclo-
nal antibody against proMBP (Fig. 1B), con¢rming our inter-
pretation. Analysis of proMBP expressed alone shows that the
vast majority of the protein migrates as a monomer of ap-
proximately 28 kDa (Fig. 1C, lane 2). Traces of dimeric
proMBP appear to be present, but no proMBP multimers
can be detected.
In human pregnancy, PAPP-A and proMBP are synthe-
sized separately in di¡erent cell types of the placenta [14] ;
yet the vast majority (approximately 99%) of circulating
PAPP-A is complexed to proMBP [21]. In accordance with
this, we ¢nd that the recombinant PAPP-A/proMBP complex
is also formed speci¢cally when PAPP-A and proMBP syn-
thesized separately are incubated. We used 20 nM of PAPP-A
and 200 nM of proMBP, re£ecting the average concentrations
of both components in pregnancy plasma, and also the molar
ratio between the two [30]. The complex formation was moni-
tored by SDS^PAGE (Fig. 2A) and by a complex-speci¢c
ELISA, in which a PAPP-A mAb was used for catching
and a proMBP mAb for detection (Fig. 2B). Under the cur-
rent conditions and concentrations used, the vast majority of
PAPP-A was covalently bound to proMBP after about 48 h of
incubation. The amount of complex measured at the plateau
level (20 nM) is equal to the molar amount of PAPP-A added
to the reaction, further demonstrating that the complex
formed has a 2:2 stoichiometry. A similar experiment was
carried out in which the concentration of proMBP was low-
ered to 40 nM (Fig. 2A). As expected, PAPP-A is converted
into PAPP-A/proMBP complex at a slower rate, and the pla-
Fig. 1. In vitro formation of the PAPP-A/proMBP complex by co-
expression of PAPP-A and proMBP cDNA in human embryonic
kidney 293T cells. A: Culture supernatants from cells transfected
with proMBP cDNA (lane 1), PAPP-A cDNA (lane 2), or PAPP-A
and proMBP cDNA together (lane 4) were separated by non-reduc-
ing SDS^PAGE (3^8% gels) and analyzed by Western blotting using
a monoclonal antibody against PAPP-A. Native PAPP-A/proMBP
isolated from pregnancy serum is shown for comparison (lane 3).
B: A similar experiment using a proMBP mAb. C: Culture superna-
tants from cells transfected with empty vector (lane 1), or with
proMBP wild-type cDNA (lane 2) or proMBP-C51S/C169S cDNA
(lane 3) were separated by non-reducing SDS^PAGE (10^20% gel)
and analyzed by Western blotting using a monoclonal antibody
against proMBP.
 
Fig. 2. In vitro formation of the PAPP-A/proMBP complex by incu-
bation of recombinant PAPP-A and proMBP synthesized separately.
A: Cells were transfected separately with PAPP-A and proMBP
cDNA, and culture supernatants containing PAPP-A (20 nM) and
proMBP (200 nM), respectively, were mixed and incubated at 37‡C
after quanti¢cation by ELISA. Samples taken out at de¢ned time
points, as indicated, were separated by SDS^PAGE and analyzed
by Western blotting with a PAPP-A monoclonal antibody. After 4 h
of incubation, recombinant PAPP-A/proMBP complex could be de-
tected, and after 24 h, very little uncomplexed PAPP-A was seen.
B: The amount of complex, as estimated using an ELISA speci¢c
for the PAPP-A/proMBP complex, was measured in samples from a
similar experiment and plotted against time (unbroken line). The
plateau level of complex, reached after about 50 h (20 nM, 4.0 Wg/
ml), corresponded to the total amount of PAPP-A measured at 0 h
and 72 h (not shown), demonstrating that the complex formed has
a 2:2 stoichiometry. A similar experiment is shown in which the
concentration of proMBP was lowered to 40 nM (dashed line).
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teau level is not reached within 72 h. At equimolar concen-
trations (20 nM of both PAPP-A and proMBP), about 10 nM
of complex had formed after 72 h (not shown).
3.2. Substitution of proMBP cysteine residues abrogates
complex formation
The complete disul¢de pattern of the 2:2 PAPP-A/proMBP
complex isolated from pregnancy serum was recently solved
[31]. Within this complex, each PAPP-A subunit is connected
to a proMBP subunit by two disul¢de bridges, which involve
Cys-51 and Cys-169 of proMBP. Thus, to obtain a variant of
proMBP unable to form those two interchain disul¢des, we
made an expression construct encoding mutated proMBP, in
which both of these residues are substituted by serine,
proMBP-C51S/C169S. Expressed alone, this mutant migrates
like wild-type proMBP in SDS^PAGE (Fig. 1C, lanes 2 and
3). Importantly, when proMBP-C51S/C169S is incubated with
wild-type PAPP-A, the covalent complex is not formed (Fig.
3). The same observation was made with co-expression experi-
ments (not shown).
This result provides us with a tool to study the implications
of covalent linkage of the two proteins. In addition, it also
further emphasizes that the process of complex formation
between PAPP-A and proMBP is highly speci¢c, even though
proMBP may contain unpaired cysteine residues with free
sulfhydryl (^SH) groups [31]. In the mature MBP, such cys-
teine residues are known to promote (self)polymerization [32].
3.3. Inhibition of PAPP-A by proMBP requires covalent
complex formation
We then compared the proteolytic activity of recombinant
PAPP-A dimer with the activity of the recombinant PAPP-A/
proMBP complex. In a time course experiment using IGFBP-
4 as the substrate, we found that PAPP-A alone rapidly
cleaved IGFBP-4, whereas the recombinant complex cleaved
very little IGFBP-4 (Fig. 4A). This experiment is in agreement
with our earlier ¢nding that the speci¢c activity of the PAPP-
A/proMBP complex of pregnancy serum is negligible com-
pared to that of the recombinant PAPP-A dimer [21]. Previ-
ously, we were unable to exclude an e¡ect of an unidenti¢ed
inhibitory component. The experiments presented here con-
clusively demonstrate that proMBP functions as a proteinase
inhibitor of PAPP-A. The weak, residual activity of the re-
combinant PAPP-A/proMBP complex (see inset of Fig. 4A) is
likely explained by incomplete complex formation: a small
subpopulation of the PAPP-A molecules may have escaped
complex formation with proMBP, although uncomplexed
PAPP-A could not be detected by Western blotting. Alterna-
tively, some PAPP-A dimers may bind only one proMBP
molecule in a partially inhibited, 2:1 complex. We are cur-
rently unable to distinguish between these two possibilities. It
should be stressed, as irreversibility of the process of complex
formation can reasonably be assumed, that estimation of a
proMBP Ki value is meaningless.
Of particular interest, when a similar experiment was car-
ried out using the proMBP-C51S/C169S mutant, no reduction
of the proteolytic activity of PAPP-A was seen (Fig. 4A). This
strongly suggests that proMBP must be covalently bound to
PAPP-A to function as an inhibitor. The same conclusion was
drawn from similar experiments using IGFBP-5 (Fig. 4B) or
IGFBP-2 (not shown) as PAPP-A substrates. Curiously, the
residual proteolytic activity of the recombinant PAPP-A/
proMBP complex appeared to be slightly higher towards
IGFBP-5 when compared to IGFBP-4 and -2.
To eliminate the possibility that the proMBP-C51S/C169S
mutant lacks inhibitory potential as a hypothetical, non-cova-
lent inhibitor because it is altered structurally in a non-speci¢c
manner, we also carried out measurements of proteolytic ac-
tivity against the IGFBPs immediately after the mixing of
PAPP-A and wild-type proMBP, i.e. before a signi¢cant
amount of complex had formed. As we see no di¡erence in
activity with and without wild-type proMBP (Fig. 4C), this
experiment conclusively demonstrates that proMBP is only
inhibitory when covalently bound to PAPP-A.
A faint band is present above the 400 kDa PAPP-A dimer
in lane 1 of Fig. 3. We variably observe this in Western blots
of PAPP-A (it amounts to less than 1% of the PAPP-A im-
munoreactivity in the similar experiment of Fig. 1A, lane 1).
Based on its lack of reactivity with proMBP antibodies (Fig.
2B, lane 3), this band does not represent PAPP-A/proMBP
complex, hypothetically formed from endogenous proMBP of
the mammalian cell line used.
3.4. The inhibitory mechanism does not involve a cysteine
switch
For protein inhibitors of proteinases, possible modes of in-
hibition generally include (1) binding directly to the active site
in a substrate-like manner, (2) binding adjacent to the active
site (or to an exosite) indirectly preventing substrate binding,
or (3) binding distant from the active site thereby allosterically
preventing proteolysis [33]. The inhibitory activity of the vast
majority of known proteinase inhibitors is based on non-co-
valent interaction [33], but the serpins (serine proteinase in-
hibitors) [34] and K2-macroglobulin [35] are known to form
covalent complexes with their target endoproteases.
What is the role of the covalent, disul¢de bond connections
in the inhibited PAPP-A/proMBP complex? In one simple
model, the two disul¢des serve to increase the binding energy
between PAPP-A and proMBP. ProMBP would then function
by blocking access to the active site, although it would not
Fig. 3. Substitution of Cys-51 and Cys-169 by serine abrogates com-
plex formation. Recombinant PAPP-A was incubated (48 h) with
mock medium (lane 1), with proMBP wild-type protein (lane 2), or
with a mutated variant of proMBP (proMBP-C51S/C169S) (lane 3).
Protein was visualized by Western blotting using a PAPP-A mono-
clonal antibody.
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bind directly to the substrate binding site of the active site.
The disul¢de structure of the PAPP-A/proMBP complex sug-
gests that proMBP interacts with the proteolytic domain of
PAPP-A and therefore likely is located in close proximity to
the active site in the three-dimensional structure. In an alter-
native model, as disul¢de bonds are formed and probably also
broken in the process of complex formation, a conformational
change of PAPP-A may allosterically cause it to become in-
active. The latter model is di⁄cult to evaluate, as the pattern
of disul¢de bonds is only resolved for the PAPP-A/proMBP
complex, not the uncomplexed PAPP-A dimer.
We speculated that a side chain sulfur atom of a proMBP
cysteine residue not engaged in a disul¢de bond might interact
directly with the active site zinc atom of PAPP-A. Such inter-
action could critically contribute to positioning and/or bind-
ing of proMBP to the active site of PAPP-A, in analogy with
the cysteine switch mechanism known to operate in latent
collagenase [36] and other metalloproteinases [2]. As men-
tioned, based on the disul¢de structure of PAPP-A/proMBP,
speci¢c cysteine residues of proMBP could potentially func-
tion in this manner, Cys-89, Cys-128, Cys-147, and Cys-201
[31].
We expressed proMBP mutants with those cysteines indi-
vidually substituted by serine, proMBP-C89S, proMBP-
C128S, proMBP-C147S, and proMBP-C201S, respectively.
All mutants formed a covalent complex with PAPP-A as
well as did wild-type proMBP (not shown), and we were un-
able to detect any di¡erence in their inhibitory properties
towards PAPP-A (Fig. 5). Based on this experiment, no cys-
 
Fig. 5. The inhibitory activity of proMBP does not depend on cys-
teine residues with free sulfhydryl groups. PAPP-A was preincu-
bated (48 h) with mock medium (open circles), with wild-type
proMBP (¢lled circles), or with mutated proMBP (proMBP-C89S,
¢lled hexagons; proMBP-C128S, ¢lled squares; proMBP-C147S,






Fig. 4. Inhibition of PAPP-A by proMBP requires covalent complex
formation. Measurements of proteolytic activity were carried out us-
ing 125I-labeled IGFBPs, each cleaved at one site by PAPP-A into
two fragments of similar size. Samples were taken out at time points
from 0 to 30 min, and the percentage of intact IGFBP in each sam-
ple was determined after separation by SDS^PAGE, as illustrated in
the insets. The concentrations of all reagents were kept constant in
each experiment. A: The plot shows the proteolytic activity against
IGFBP-4 of PAPP-A preincubated (48 h) with mock medium (open
circles), with wild-type proMBP (¢lled circles), or with mutated
proMBP (proMBP-C51S/C169S), unable to form the PAPP-A/
proMBP complex (¢lled squares). The gel inset shows activity (at
t=30 min) of negative control (mock, lane 1), PAPP-A (lane 2),
PAPP-A/proMBP complex (lane 3), and PAPP-A with proMBP-
C51S/C169S (lane 4). Positions of intact (i) and cleaved (c) IGFBP-
4 are indicated. B: A similar experiment carried out with IGFBP-5
as the PAPP-A substrate. C: A similar experiment, but without pre-
incubation of PAPP-A and proMBP. The plot shows cleavage of
IGFBP-4 (¢lled diamonds) in the absence (solid line) and presence
(dotted line) of wild-type proMBP, and likewise cleavage of IGFBP-
5 (¢lled triangles) in the absence (solid line) and presence (dotted
line) of wild-type proMBP. Within the time frame of this experi-
ment, no di¡erence in proteolytic activity could be detected, in
agreement with the absence of detectable covalent complex.
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teine side chain of proMBP interacts directly with the zinc
atom of the active site of PAPP-A.
Basic residues of both IGFBP-4 and -5 are known to be
important in PAPP-A substrate recognition [37]. Even though
covalent binding of proMBP to PAPP-A is required for inhi-
bition, substrate-like interactions with basic residues of
proMBP might still be important. Further studies are required
to evaluate the possible in£uence on inhibitory activity of
individual basic proMBP residues.
3.5. Concluding remarks
We have demonstrated that proMBP forms a covalent, di-
sul¢de-bound complex with PAPP-A when the two molecules
are co-expressed in mammalian cells or incubated together
after separate synthesis. The recombinant PAPP-A/proMBP
complex forms in a speci¢c manner, and it lacks proteolytic
activity. This conclusively demonstrates that proMBP func-
tions as a proteinase inhibitor. We further show that the abil-
ity of proMBP to function as an inhibitor depends on its
covalent linkage to PAPP-A. To our knowledge, this repre-
sents a unique mode of inhibition, not paralleled by any pro-
teinase^inhibitor pair. The system we have established will
allow the process of complex formation as well as the inhib-
itory mechanism of proMBP to be further studied. We are
currently unable to distinguish between possible inhibitory
mechanisms, including steric hindrance and allosteric inhibi-
tion, but we can exclude that the inhibitory mechanism is
based on an interaction between a sulfhydryl group of
proMBP and the active site zinc atom of PAPP-A, in a cys-
teine switch-like mechanism.
Basic residues of both IGFBP-4 and -5 are known to be
important in PAPP-A substrate recognition [37]. Even though
covalent binding of proMBP to PAPP-A is required for inhi-
bition, substrate-like interactions with basic residues of
proMBP might still be important. Further studies are required
to evaluate the possible in£uence on inhibitory activity of
individual basic proMBP residues.
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